Summary
Johnson & Johnson reported a strong second quarter of 2002, demonstrating robust sales growth across its core segments. Worldwide sales increased by 10.9% to $9.07 billion compared to the same period last year. This growth was driven by solid performance in the Pharmaceutical segment, up 10.2%, and notable acceleration in Medical Devices & Diagnostics, up 13.7%. The Consumer segment also saw healthy growth of 7.8%, bolstered by key brands in skincare and nutritional products. Net earnings increased by 11.6% to $1.65 billion, with diluted earnings per share rising to $0.54 from $0.48 in the prior year's quarter. The company also repurchased a significant amount of its stock during the period, completing a $5 billion program. For the first six months of 2002, sales reached $17.82 billion, an 11.1% increase year-over-year. Net earnings for the six-month period were $3.49 billion, up 15.0% from the previous year. The company successfully integrated recent acquisitions, including Tibotec-Virco NV and Obtech Medical AG, though these resulted in after-tax charges for in-process research and development. Johnson & Johnson continues to invest in its product pipeline and research, as evidenced by increased research expenses. The company highlighted ongoing legal proceedings, particularly related to the drug PROPULSID, while expressing confidence in managing potential liabilities.
Key Highlights
- 1Worldwide sales for the second quarter of 2002 reached $9.07 billion, an increase of 10.9% compared to the prior year's quarter.
- 2Net earnings for the quarter were $1.65 billion, a 11.6% increase, with diluted EPS rising to $0.54 from $0.48.
- 3The Pharmaceutical segment showed strong growth with sales up 10.2%, driven by key products like PROCRIT/EPREX and REMICADE.
- 4The Medical Devices & Diagnostics segment experienced significant growth of 13.7%, fueled by circulatory disease management, orthopaedics, and surgical products.
- 5Johnson & Johnson completed a $5 billion stock repurchase program, demonstrating a commitment to returning capital to shareholders.
- 6The company incurred $189 million in after-tax charges for in-process research and development related to the acquisitions of Tibotec-Virco NV and Obtech Medical AG.
- 7Significant legal proceedings, particularly concerning the drug PROPULSID, are ongoing, with the company confident in managing potential liabilities.